Israeli artificial intelligence biotech startup SpotitEarly Ltd. today officially launched in the U.S. and announced that it has raised $20.3 million in new funding to scale up its U.S. presence and to strengthen its cancer detection technology.
Founded in 2020, SpotitEarly is pioneering a noninvasive breath test for early cancer detection. The company uses AI and canines to analyze volatile organic compounds in exhaled breath, identifying biomarkers associated with cancers such as breast, lung, colorectal and prostate.
Core to SpotitEarly’s offering is the LUCID platform, a platform that uses AI to process breath samples to detect cancer-related VOCs. The system integrates hardware and software to deliver accurate and scalable cancer screening solutions.
Though not yet commercially available, the breath test has demonstrated 94% accuracy in detecting multiple cancer types in a large-scale clinical trial of 1,200 people, the company said. It says the high level of accuracy highlights the potential of AI-driven breath analysis in early cancer detection.
With the funding, SpotitEarly plans to make home testing kits commercially available in the U.S. by 2026, allowing individuals to collect breath samples easily, which are then analyzed using the LUCID platform.
“While there has been movement from emerging tech companies that have shown great promise for transforming the way we screen and detect cancer, they’ve lacked accessibility and precision,” said Chief Executive Shlomi Madar. ”The opportunity to bring SpotitEarly’s innovative tech and dynamic approach to the U.S. and to drastically improve how we conquer a complex and persistent disease that takes the lives of millions of Americans each year, is both a great honor and responsibility.”
Participating in the funding round were Hanaco Venture Capital Ltd., Menomedin Venture Capital Ltd., Jeff Swartz, former CEO of Timberland Co., and Avishai Abrahami, CEO of Wix.com Ltd.
SpotitEarly has also appointed U.S.-based advisers to its scientific board. They include Dr. David Sidransky, a leading expert and pioneer in the molecular genetic detection of cancer, Jonathan Fleming, senior lecturer at the Massachusetts Institute of Technology, and Dr. Len Lichtenfeld, former deputy chief medical officer of the American Cancer Society.
Image: SpotitEarly
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mission to provide free, deep, and relevant content.
Join our community on YouTube
Join the community that includes more than 15,000 #CubeAlumni experts, including Amazon.com CEO Andy Jassy, Dell Technologies founder and CEO Michael Dell, Intel CEO Pat Gelsinger, and many more luminaries and experts.
THANK YOU
